Zions Bancorp (ZION) EPS Estimated At $0.73; Last Week Alimera Sciences (ALIM) Coverage

September 22, 2017 - By Clifton Ray

Analysts expect Zions Bancorp (NASDAQ:ZION) to report $0.73 EPS on October, 23.They anticipate $0.16 EPS change or 28.07% from last quarter’s $0.57 EPS. ZION’s profit would be $147.58 million giving it 15.53 P/E if the $0.73 EPS is correct. After having $0.73 EPS previously, Zions Bancorp’s analysts see 0.00% EPS growth. It closed at $45.36 lastly. It is down 48.85% since September 22, 2016 and is uptrending. It has outperformed by 32.15% the S&P500.

Among 3 analysts covering Alimera Sciences (NASDAQ:ALIM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alimera Sciences had 11 analyst reports since August 12, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Alimera Sciences Inc (NASDAQ:ALIM) rating on Wednesday, August 12. Cantor Fitzgerald has “Buy” rating and $10 target. The rating was maintained by H.C. Wainwright with “Buy” on Friday, August 4. As per Wednesday, August 30, the company rating was maintained by H.C. Wainwright. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 11 report. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, July 11. The stock of Alimera Sciences Inc (NASDAQ:ALIM) earned “Buy” rating by Cowen & Co on Thursday, August 3. The stock of Alimera Sciences Inc (NASDAQ:ALIM) earned “Market Perform” rating by Cowen & Co on Friday, May 6. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, January 19 report. Cowen & Co maintained Alimera Sciences Inc (NASDAQ:ALIM) on Tuesday, July 25 with “Buy” rating. The stock of Alimera Sciences Inc (NASDAQ:ALIM) has “Outperform” rating given on Friday, September 16 by Cowen & Co. See Alimera Sciences Inc (NASDAQ:ALIM) latest ratings:

30/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
03/08/2017 Broker: Cowen & Co Rating: Buy New Target: $3.0000 Maintain
04/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain
25/07/2017 Broker: Cowen & Co Rating: Buy New Target: $3.0000 Maintain
26/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain
11/07/2017 Broker: Cowen & Co Rating: Buy New Target: $3.0000 Maintain
11/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain

Alimera Sciences, Inc. is a pharmaceutical company. The company has market cap of $89.77 million. The Firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It currently has negative earnings. The Firm operates through two divisions: U.S. and International.

The stock 0.39% or $0 on September 21, reaching $1.3. It is down 0.67% since September 22, 2016 and is uptrending. It has underperformed by 16.03% the S&P500.

Investors sentiment increased to 1.07 in Q2 2017. Its up 0.07, from 1 in 2017Q1. It improved, as 4 investors sold Alimera Sciences Inc shares while 10 reduced holdings. 8 funds opened positions while 7 raised stakes. 25.49 million shares or 0.63% less from 25.65 million shares in 2017Q1 were reported. 974,318 are owned by Acuta Prtnrs Ltd Liability Co. Art Lc holds 0.01% of its portfolio in Alimera Sciences Inc (NASDAQ:ALIM) for 83,092 shares. Commercial Bank Of Montreal Can has 0% invested in Alimera Sciences Inc (NASDAQ:ALIM). Geode Ltd Limited Liability Company stated it has 156,604 shares or 0% of all its holdings. Northern Tru holds 0% in Alimera Sciences Inc (NASDAQ:ALIM) or 102,792 shares. Deerfield invested in 0.35% or 4.77 million shares. 18,966 are owned by Guggenheim Cap Ltd Liability Company. Inv Centers Of America holds 24,000 shares. Bridgeway Mgmt owns 389,825 shares for 0.01% of their portfolio. Goldman Sachs Grp Inc Incorporated holds 0% or 303,823 shares. Morgan Stanley, New York-based fund reported 400 shares. Blackrock has invested 0% in Alimera Sciences Inc (NASDAQ:ALIM). Armistice Capital Lc has 1.05% invested in Alimera Sciences Inc (NASDAQ:ALIM). Savings Bank Of Mellon Corp reported 27,227 shares. Deutsche Bancorp Ag has invested 0% of its portfolio in Alimera Sciences Inc (NASDAQ:ALIM).

Investors sentiment increased to 1.09 in 2017 Q2. Its up 0.13, from 0.96 in 2017Q1. It is positive, as 57 investors sold Zions Bancorp shares while 130 reduced holdings. 68 funds opened positions while 136 raised stakes. 183.76 million shares or 0.95% less from 185.52 million shares in 2017Q1 were reported. 29,255 were accumulated by Chicago Equity Ltd Llc. Ejf Limited Company holds 6.55% of its portfolio in Zions Bancorp (NASDAQ:ZION) for 1.76 million shares. De Burlo Group Inc has invested 0.35% in Zions Bancorp (NASDAQ:ZION). Oppenheimer Asset Management owns 0.03% invested in Zions Bancorp (NASDAQ:ZION) for 22,398 shares. Reilly Financial Advsr Ltd Llc invested 0% of its portfolio in Zions Bancorp (NASDAQ:ZION). The Australia-based Westpac Bk Corp has invested 0% in Zions Bancorp (NASDAQ:ZION). Cibc Ww reported 28,635 shares. Daiwa Gru holds 0% or 6,000 shares in its portfolio. Adage Cap Ptnrs Group Incorporated Ltd Liability Corporation reported 439,000 shares. Whittier Trust Of Nevada Inc invested in 0% or 303 shares. British Columbia Inv Mgmt has invested 0.05% of its portfolio in Zions Bancorp (NASDAQ:ZION). 2,997 were reported by Exane Derivatives. The Quebec – Canada-based Caisse De Depot Et Placement Du Quebec has invested 0% in Zions Bancorp (NASDAQ:ZION). Pennsylvania-based Glenmede Trust Na has invested 0% in Zions Bancorp (NASDAQ:ZION). Affinity Invest Advsrs Limited reported 0.25% stake.

Zions Bancorporation is a financial holding company. The company has market cap of $9.17 billion. The Firm conducts its banking activities through separately managed and branded divisions, including Zions Bank, Amegy Bank, California Bank & Trust, National Bank of Arizona, Nevada State Bank , Vectra Bank Colorado, The Commerce Bank of Washington (TCBW) and Other. It has a 18.03 P/E ratio. It focuses on providing community banking services through its business lines, including small and medium-sized business and corporate banking; commercial and residential development, construction and term lending; retail banking; treasury cash management and related services and products; residential mortgage servicing and lending; trust and wealth management; limited capital markets activities, including municipal finance advisory and underwriting, and investment activities.